'Saudi Arabia committed to promoting dialogue on role of culture in sustainable development'    Arab Coalition foils Houthis' bid to target Saudi commercial ship    Saudi Arabia, UK seek to boost cooperation in space economy    Malaysia foreign minister thanks Saudi Arabia as third plane COVID-19 aid reaches Kuala Lumpur    UK defends France quarantine decision as Paris slams 'discriminatory' rule    UN chief urges action as COVID-19 leaves 'many millions' more vulnerable to human trafficking    COVID-19 vaccine shipments boost for Africa    From electric dreams to supercharged reality: the road race to a clean energy future    Prince Abdulaziz: Saudi Arabia will be engine for digital transformation in energy sector    Saudi Arabia opens doors for vaccinated tourists from Aug. 1    Economy minister: Opportunities will exceed $3 trillion within 5 years    Bu Arish sets his new record with 55th rank in men's 100m butterfly    Simone Biles says fans' support helping her realize she's more than gold medals    Hidilyn Diaz wins Philippines' first Olympic gold medal with weightlifting    Saudi exports jump 120% to SR82.2 billion in May    UAE government starts granting 'golden' visas to resident doctors    Progress on tobacco fight, but new nicotine products pose increasing threat    KAMC in Makkah performs 6th artificial heart transplant surgery    Clubhouse says no data breach after reports of 3.8bn phone numbers of users being sold    Custodian of the Two Holy Mosques Directs KSrelief to Urgently Provide Malaysia with Medical, Preventive Equipment and Supplies to Address COVID-19 Pandemic    Weather Forecast for Sunday    Custodian of the Two Holy Mosques Congratulates President of Maldives on Independence Day    RSNF Commander Patronizes Ceremonial Launching of His Majesty's Ship "Jazan"    OIC Condemns Houthi Attempts to Target Civilians in Saudi Arabia    Kuwait Records 987 New Infections of Coronavirus    Philippines evacuates thousands as monsoon rains flood cities, provinces    Heavy rain in India triggers floods, landslides; at least 125 dead    Without Fans, Tokyo Olympics Kicked Off    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Dr. Mohammed Sulaiman Al-Jasser, Saudi Arabia's Pick to Chair IsDB Group for the next five years, unanimously approved by BoG Committee of Procedures    Britney Spears says she won't perform while under father conservatorship    Saudi Press: Fitch affirms Saudi Credit Rating at "A" with a revised outlook to stable from negative    Handled Cargo at Saudi Ports Increases during June 2021    SDAIA, DARP & STC Launch Pilgrim's Smart Bracelet (NUSK)    Tabuk sculptor spends 8 years in carving entire Holy Qur'an on 30 marble slabs    2 Goals by Diaz Gives Colombia 3rd Place at Copa America    Yusuf Khan is dead, long live Dilip Kumar    Legendary actor Dilip Kumar, 98, passes away, and with him an era    Saudi Cinema Night at Arab World Institute in Paris Kicks Off    KSU Leads Joint International Scientific Project for Early Detection of Breast Cancer    Saudi Arabia to Participate in Cannes Film Festival 2021    Arab Cup U-17 Championship Draw Saudi Arabia, Morocco, Palestine, Kuwait, in the 1st Group    Bollywood star Aamir and wife Kiran separate after 15 years    AWI Hosts Saudi Cinema Nights in Paris    Saudi Uner-20 Football National Team Beats Egyptian Counterpart to Qualify for Arab Youth Cup Championships' Final    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



US FDA adviser resigns over approval of new Alzheimer's drug
Published in The Saudi Gazette on 10 - 06 - 2021

A member of a US Food and Drug Administration advisory committee said on Wednesday he had resigned over the agency's approval of a new Alzheimer's drug.
The FDA approved aducanumab, to be sold under the brand name Aduhelm, this week over the objections of its advisory Peripheral and Central Nervous System Drugs Advisory Committee.
Mayo Clinic neurologist Dr. David Knopman said on Wednesday he had resigned from the committee in protest.
"I resigned from the PCNS committee because if I ever were asked to serve on a future panel, I wouldn't have wanted to be treated in the disrespectful way that the aducanumab external advisers were treated," he said via email.
"While I disagree with the decision to approve aducanumab, we in the clinical care and clinical research worlds will simply have to learn to adapt to the new circumstances."
The FDA's advisers said there wasn't enough evidence to support approving the drug, which is given by infusion. Initial trials of the treatment, meant to be given to people very early in the course of disease before they develop dementia, did not indicate it helped at all. But the drug's maker, Biogen, re-analyzed data and said there was an indication it might help some patients.
The Washington Post first reported Knopman's resignation. A second member of the committee, Dr. Joel Perlmutter, did not immediately respond to CNN's queries about a report in STAT News he had also resigned.
The FDA had not approved a novel therapy for Alzheimer's disease since 2003. There is no cure for the disease, and current treatments can slow progression but none help for long. The Alzheimer's Association estimates that more than 6 million Americans have Alzheimer's related dementia.
Clinical trials of aducanumab were stopped in 2019 because they failed to show the drug was effective.
But the drug's maker, Biogen, re-analyzed the data and said it showed some patients who got high doses of the drug had not improved but had shown a slower rate of decline than other patients.
The PCNS committee met in November and voted on several questions about evidence of the drug's effectiveness.
They voted against the suggestion the drug could help patients, and came down as uncertain on the question of whether the drug had any effects on the brain.
While the FDA is not bound by the advice of its committees, it usually follows them, so the decision to approve the drug was unusual and controversial. Advocates for approval said the need is desperate, while opponents say the drug — priced at $56,000 a year — would bring in billions for Biogen while failing to help patients.
Aducanumab is a monoclonal antibody designed to pull a substance called amyloid out of the brain. Amyloid is one of the brain-clogging hallmarks of Alzheimer's, although Alzheimer's specialists are not in complete agreement about whether it's a cause or a symptom of the disease.
But the FDA decided the evidence showed the drug, given as an infusion, could reduce levels of amyloid in the brain and said this might help some patients.
The approval is for use in patients with mild cognitive impairment, which is the memory loss and loss of clear thinking ability that often progresses to dementia.


Clic here to read the story from its source.